Altimmune, Inc. filings document a late clinical-stage biopharmaceutical issuer focused on pemvidutide for serious liver diseases, along with the capital structure used to support that development. Its Form 8-K reports cover operating-result announcements, underwriting agreements, registered direct and at-the-market equity programs, pre-funded warrants, common stock warrants and loan agreement amendments.
Altimmune’s proxy and annual meeting materials disclose shareholder voting matters, governance procedures, executive compensation information and amendments to its certificate of incorporation, including authorized-share matters. The filings also identify its common stock as listed on The Nasdaq Global Market under the symbol ALT.
Altimmune, Inc. is conducting an underwritten offering of 64,250,000 shares of common stock together with accompanying common stock warrants and, in lieu of certain shares to some investors, pre-funded warrants to purchase up to 10,750,000 shares. The offering includes common stock warrants exercisable for up to 75,000,000 shares with a $3.00 exercise price.
Proceeds (net ~$211.2M) are intended to fund a planned global Phase 3 trial of pemvidutide in MASH and for working capital and general corporate purposes. The common stock warrants expire on the earlier of five years after issuance or 45 days after a public announcement of a successful Phase 3 pemvidutide readout. The pre-funded warrants have a $0.001 exercise price and do not expire.
Altimmune, Inc. filed a preliminary prospectus supplement to offer shares of common stock, pre-funded warrants and common stock warrants pursuant to its shelf registration statements. The company intends to use net proceeds to fund a planned global Phase 3 trial of pemvidutide in MASH and for working capital and general corporate purposes. The supplement notes pemvidutide Phase 2b topline efficacy (MASH resolution: 58.2% and 52.1% for two doses versus 19.9% for placebo) and that the FDA granted Breakthrough Therapy Designation in MASH. The filing discloses 110,882,735 shares outstanding as of December 31, 2025 and that the company filed to increase authorized common shares to 400,000,000 on April 16, 2026. The prospectus estimates available cash is expected to fund operations through a topline Phase 3 readout anticipated in the first half of 2029, subject to assumptions.
Altimmune, Inc. reported results from its 2026 Annual Meeting and a key charter change. Stockholders approved an amendment to increase authorized common shares from 200,000,000 to 400,000,000, giving the company more capacity to issue stock in the future.
As of March 13, 2026, 130,105,177 shares were outstanding and entitled to vote, with 88,270,365 shares represented, a 67.8% quorum. Stockholders elected all director nominees, ratified Ernst & Young LLP as auditor, approved the advisory say-on-pay vote, expanded the 2019 Employee Stock Purchase Plan reserve from 403,500 to 1,108,827 shares, and authorized potential adjournment of the meeting to solicit additional proxies.
Altimmune, Inc. director John Gill reported an open-market purchase of 9,200 shares of common stock at a weighted average price of $3.4076 per share. After this transaction, he directly owns 21,700 Altimmune shares. The shares were bought in multiple trades between $3.4050 and $3.4080.
Altimmune, Inc. Chief Financial Officer Gregory L. Weaver completed an open-market purchase of 10,000 shares of common stock. The transaction, dated April 1, 2026, was executed at a weighted average price of $3.1499 per share and was made directly.
Following this purchase, Weaver directly owns 38,078 shares of Altimmune common stock. According to the footnote, the shares were bought in multiple trades, with prices ranging from $3.1450 to $3.1499 per share.
Altimmune, Inc. President and CEO Jerome Benedict Durso reported an open-market purchase of 15,000 shares of the company’s common stock at $3.14 per share.
Following this transaction, his directly held Altimmune common stock position increased to 47,500 shares.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting its position in Altimmune Inc. The filing states 0 shares beneficially owned and 0% of the class. The amendment explains an internal realignment and separate reporting by Vanguard subsidiaries in accordance with SEC Release No. 34-39538.
Altimmune, Inc. has released its 2026 proxy for a virtual annual meeting on April 16, 2026. Shareholders of record as of March 13, 2026, when 130,105,177 common shares were entitled to vote, are asked to elect nine directors and ratify Ernst & Young LLP as auditor.
Investors will also cast an advisory vote on executive pay, consider doubling authorized common stock from 200,000,000 to 400,000,000 shares, and vote on expanding the 2019 Employee Stock Purchase Plan reserve from 403,500 to 1,108,827 shares. A proposal to allow adjournment to solicit more proxies is also included.
Altimmune, Inc. Chief Financial Officer Gregory L. Weaver bought 5,000 shares of the company’s common stock in an open-market purchase at a price of $3.54 per share. After this transaction, he directly owns 28,078 common shares of Altimmune.